Well-travelled Abizer Gaslightwal gets top job at Akari

20 March 2025

Akari Therapeutics (Nasdaq: AKTX), a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive.

Mr Gaslightwala, who will take over on April 21, is a biotech and pharma industry veteran with 25 years of experience in the development and commercialization of novel medicines across a range of companies and therapeutic areas.

He joins Akari having most recently served as the senior vice president and franchise head for US Oncology at Ireland-based biopharma Jazz Pharmaceuticals (Nasdaq: JAZZ), where he was responsible for a portfolio of products that have total annual sales reaching $1 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK